184 related articles for article (PubMed ID: 37197477)
1. Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.
Kim DR; Orr MJ; Kwong AJ; Deibler KK; Munshi HH; Bridges CS; Chen TJ; Zhang X; Lacorazza HD; Scheidt KA
ACS Med Chem Lett; 2023 May; 14(5):606-613. PubMed ID: 37197477
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for producing selective MAP2K7 inhibitors.
Murakawa Y; Valter S; Barr H; London N; Kinoshita T
Bioorg Med Chem Lett; 2020 Nov; 30(22):127546. PubMed ID: 32931911
[TBL] [Abstract][Full Text] [Related]
3. A crucial role of Cys218 in configuring an unprecedented auto-inhibition form of MAP2K7.
Sogabe Y; Hashimoto T; Matsumoto T; Kirii Y; Sawa M; Kinoshita T
Biochem Biophys Res Commun; 2016 Apr; 473(2):476-81. PubMed ID: 26987717
[TBL] [Abstract][Full Text] [Related]
4. Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities.
Schröder M; Tan L; Wang J; Liang Y; Gray NS; Knapp S; Chaikuad A
Cell Chem Biol; 2020 Oct; 27(10):1285-1295.e4. PubMed ID: 32783966
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
6. Stress-activated kinase pathway alteration is a frequent event in bladder cancer.
Otto KB; Acharya SS; Robinson VL
Urol Oncol; 2012; 30(4):415-20. PubMed ID: 22154358
[TBL] [Abstract][Full Text] [Related]
7. The potential for signal integration and processing in interacting MAP kinase cascades.
Schwacke JH; Voit EO
J Theor Biol; 2007 Jun; 246(4):604-20. PubMed ID: 17337011
[TBL] [Abstract][Full Text] [Related]
8. Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.
Shraga A; Olshvang E; Davidzohn N; Khoshkenar P; Germain N; Shurrush K; Carvalho S; Avram L; Albeck S; Unger T; Lefker B; Subramanyam C; Hudkins RL; Mitchell A; Shulman Z; Kinoshita T; London N
Cell Chem Biol; 2019 Jan; 26(1):98-108.e5. PubMed ID: 30449673
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Chen TJ; Du W; Junco JJ; Bridges CS; Shen Y; Puppi M; Rabin KR; Lacorazza HD
Oncotarget; 2021 Aug; 12(18):1787-1801. PubMed ID: 34504651
[TBL] [Abstract][Full Text] [Related]
10. ZPK/DLK and MKK4 form the critical gateway to axotomy-induced motoneuron death in neonates.
Itoh T; Horiuchi M; Ikeda RH; Xu J; Bannerman P; Pleasure D; Penninger JM; Tournier C; Itoh A
J Neurosci; 2014 Aug; 34(32):10729-42. PubMed ID: 25100604
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Shen Y; Park CS; Suppipat K; Mistretta TA; Puppi M; Horton TM; Rabin K; Gray NS; Meijerink JPP; Lacorazza HD
Leukemia; 2017 Jun; 31(6):1314-1324. PubMed ID: 27872496
[TBL] [Abstract][Full Text] [Related]
12. Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Shen Y; Chen TJ; Lacorazza HD
Exp Hematol; 2017 Sep; 53():16-25. PubMed ID: 28479419
[TBL] [Abstract][Full Text] [Related]
13. Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia.
Winchester CL; Ohzeki H; Vouyiouklis DA; Thompson R; Penninger JM; Yamagami K; Norrie JD; Hunter R; Pratt JA; Morris BJ
Hum Mol Genet; 2012 Nov; 21(22):4910-21. PubMed ID: 22899651
[TBL] [Abstract][Full Text] [Related]
14. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
15. 5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner.
Sogabe Y; Matsumoto T; Hashimoto T; Kirii Y; Sawa M; Kinoshita T
Bioorg Med Chem Lett; 2015 Feb; 25(3):593-6. PubMed ID: 25529738
[TBL] [Abstract][Full Text] [Related]
16. c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons.
Repici M; Mare L; Colombo A; Ploia C; Sclip A; Bonny C; Nicod P; Salmona M; Borsello T
Neuroscience; 2009 Mar; 159(1):94-103. PubMed ID: 19135136
[TBL] [Abstract][Full Text] [Related]
17. High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.
Kinoshita T; Hashimoto T; Sogabe Y; Fukada H; Matsumoto T; Sawa M
Biochem Biophys Res Commun; 2017 Nov; 493(1):313-317. PubMed ID: 28890347
[TBL] [Abstract][Full Text] [Related]
18. Mitogen Kinase Kinase (MKK7) Controls Cytokine Production In Vitro and In Vivo in Mice.
Caliz AD; Yoo HJ; Vertii A; Dolan AC; Tournier C; Davis RJ; Keaney JF; Kant S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502275
[TBL] [Abstract][Full Text] [Related]
19. Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
Ma B; Metrick CM; Gu C; Hoemberger M; Bajrami B; Bame E; Huang J; Mingueneau M; Murugan P; Santoro JC; Tang H; Wang T; Hopkins BT
Bioorg Med Chem Lett; 2022 Mar; 60():128549. PubMed ID: 35041943
[TBL] [Abstract][Full Text] [Related]
20. Mice haploinsufficient for Map2k7, a gene involved in neurodevelopment and risk for schizophrenia, show impaired attention, a vigilance decrement deficit and unstable cognitive processing in an attentional task: impact of minocycline.
Openshaw RL; Thomson DM; Penninger JM; Pratt JA; Morris BJ
Psychopharmacology (Berl); 2017 Jan; 234(2):293-305. PubMed ID: 27774567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
